Bradley Herring Sells 4,134 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) CFO Bradley Herring sold 4,134 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $41,877.42. Following the transaction, the chief financial officer now owns 266,369 shares of the company’s stock, valued at $2,698,317.97. This trade represents a 1.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Bradley Herring also recently made the following trade(s):

• On Friday, December 20th, Bradley Herring sold 24,443 shares of Enfusion stock. The stock was sold at an average price of $10.61, for a total value of $259,340.23.

Enfusion Stock Performance

NYSE:ENFN opened at $9.97 on Friday. The company has a market capitalization of $1.28 billion, a PE ratio of 249.31, a P/E/G ratio of 3.98 and a beta of 0.95. Enfusion, Inc. has a fifty-two week low of $7.52 and a fifty-two week high of $11.38. The company has a 50 day simple moving average of $10.11 and a two-hundred day simple moving average of $9.20.

Institutional Investors Weigh In On Enfusion

Several large investors have recently modified their holdings of ENFN. Centiva Capital LP grew its holdings in Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after acquiring an additional 1,227 shares during the period. Harbor Capital Advisors Inc. increased its holdings in Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after purchasing an additional 1,315 shares in the last quarter. Azora Capital LP lifted its stake in Enfusion by 6.8% in the third quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after buying an additional 1,890 shares during the period. 272 Capital LP grew its position in shares of Enfusion by 1.5% during the 2nd quarter. 272 Capital LP now owns 139,180 shares of the company’s stock worth $1,186,000 after buying an additional 2,000 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Enfusion by 27.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after acquiring an additional 4,239 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ENFN has been the topic of several research reports. Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Stifel Nicolaus upped their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.25.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.